LeonaBio (LONA) Income from Continuing Operations (2019 - 2026)
LeonaBio (LONA) reported Income from Continuing Operations of 17214000.0 for Q1 2026, down 80.52% year-over-year from 88349141.01 in Q1 2025, and up 78.09% quarter-over-quarter from 78565000.0 in Q4 2025.
LeonaBio (LONA) Income from Continuing Operations (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has 8 years of Income from Continuing Operations data on file, last reported at 17214000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 17214000.0, down 80.52% year-over-year; the trailing twelve-month figure through Mar 2026 was 109944000.0 (down 32.86% YoY), and the FY2025 annual result was 105610000.0, down 351933.33% from the prior year.
- Income from Continuing Operations grew to 17214000.0 in Q1 2026 per LONA's latest filing, from 78565000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 6874000.0 in Q3 2025 and troughed at 78565000.0 in Q4 2025.
- A 5-year average of 26462588.24 and a median of 27687000.0 in 2024 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 76.79% in 2025 and fell as far as 404.72% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 32927000.0 in 2022, then grew by 11.88% to 29014000.0 in 2023, then soared by 46.35% to 15566000.0 in 2024, then slumped by 404.72% to 78565000.0 in 2025, then soared by 78.09% to 17214000.0 in 2026.
- Business Quant data shows LONA's Income from Continuing Operations at 17214000.0 in Q1 2026, 78565000.0 in Q4 2025, and 6874000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | LeonaBio | 154.12 Mn | 86.44 Mn | - | -17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.21 Mn |
| Dec 31, 2025 | -78.57 Mn |
| Sep 30, 2025 | -6.87 Mn |
| Jun 30, 2025 | -7.29 Mn |
| Mar 31, 2025 | -9.54 Mn |
| Dec 31, 2024 | -15.57 Mn |
| Sep 30, 2024 | -29.62 Mn |
| Jun 30, 2024 | -28.03 Mn |
| Mar 31, 2024 | -27.69 Mn |
| Dec 31, 2023 | -29.01 Mn |
| Sep 30, 2023 | -35.04 Mn |
| Jun 30, 2023 | -31.64 Mn |
| Mar 31, 2023 | -29.77 Mn |
| Dec 31, 2022 | -32.93 Mn |
| Sep 30, 2022 | -24.13 Mn |
| Jun 30, 2022 | -23.57 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -18.78 Mn |
| Sep 30, 2021 | -17.83 Mn |
| Jun 30, 2021 | -16.64 Mn |